FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's...
Source: prnewswire.com